08:45 AM EDT, 07/29/2024 (MT Newswires) -- Guardant Health ( GH ) said Monday the US Food and Drug Administration has approved its Shield blood test for colorectal cancer screening in adults aged 45 years and older.

The company said the blood test is the first to be approved by the FDA as a primary screening option for colorectal cancer and the first to meet Medicare coverage requirements.

Shares of Guardant Health ( GH ) were up more than 5% in recent premarket activity Monday.

Price: 34.67, Change: +1.67, Percent Change: +5.06